FDA turns back DBV Technologies’ peanut allergy patch, raising questions about its design

A peanut allergy patch based on new delivery technology has hit a snag at the FDA.

The agency on Monday turned down DBV Technologies’ Viaskin Peanut patch for children between the ages of 4 and 11, raising concerns about the patch itself. Built on the French company’s Viaskin platform, it's designed to deliver small, controlled amounts of peanut allergens through the skin to help desensitize the immune system and dampen its reactions.